5-fluorouracil for actinic keratoses

References

• Longley DB, Harkin DP, Johnson PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer3, 330–338 (2003).
   PubMed Web of Science ®Google Scholar
• Zhang N, Yin Y, Xu SJ, Chen WS. 5-fluorouracil: mechanisms of resistance and reversal strategies. Molecules13, 1551–1569 (2008).
   PubMed Web of Science ®Google Scholar
• Showalter SL, Showalter TN, Witkiewicz A et al. Evaluating the drug relationship between thymidilate synthase expression and tumor response to 5-fluorouracil. Is it time to move forward? Cancer Biol. Ther.1, 986–994 (2008).
   Google Scholar
• Arias JL. Novel strategies to improve the anticancer action of 5-fluorouracil by using drug delivery systems. Molecules13, 2340–2369 (2008).
   PubMed Web of Science ®Google Scholar
• Walko CM, Lindley C. Capecitabine: a review. Clin. Ther.27, 23–44 (2005).
   PubMed Web of Science ®Google Scholar
• Arango D, Corner GA, Wadler S et al. c-myc/p53 interaction determines sensitivity of human colon carcinoma cells to 5-fluorouracil in vitro and in vivo. Cancer Res.61, 4910–4915 (2001).
   PubMedGoogle Scholar
• Sachs DL, Kang S, Hammerberg C et al. Topical fluorouracil for actinic keratoses and photoaging. Arch. Dermatol.145, 659–666 (2009).
   PubMedGoogle Scholar
• Grem JL. 5-fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Invest. New Drugs18, 299–313 (2000).
   PubMed Web of Science ®Google Scholar
• Jorizzo J. Topical treatment of actinic keratosis with fluorouracil: is irritation associated with efficacy? J. Drugs Dermatol.3, 21–26 (2004).
   PubMedGoogle Scholar
• Duncan AL, Bell HK. 5-fluorouracil cream and leg ulceration. J. Plast. Reconstr. Aesthet. Surg.60, 690–669 (2007).
   PubMedGoogle Scholar
• Cartei G, Cartei F, Interlandi G et al. Oral 5-fluorouracil in squamous cell carcinoma of the skin in the aged. Am. J. Clin. Oncol.23, 181–184 (2000).
   PubMed Web of Science ®Google Scholar
• Oba K, Morita S, Tsuburaya A et al. Efficacy of adjuvant chemotherapy using oral fluorinated pyrimidines for curatively resected gastric cancer: a meta-analysis of centrally randomized controlled trials in Japan. J. Chemother.18, 311–318 (2006).
   PubMed Web of Science ®Google Scholar
• Hu JK, Li CM, Chen XZ et al. The effectiveness of intravenous 5-fluorouracil-containing chemotherapy after curative resection for gastric carcinoma: a systematic review of published randomized controlled trials. J. Chemother.19, 359–375 (2007).
   PubMed Web of Science ®Google Scholar
• Juckett G, Hartman-Adams H. Management of keloids and hypertophic scars. Am. Fam. Physician80, 253–260 (2009).
   PubMedGoogle Scholar
• Berman B, Viera MH, Amini S et al. Prevention and management of hypertrophic scars and keloids after burns in children. J. Craniofac. Surg.19, 989–1006 (2008).
   PubMed Web of Science ®Google Scholar
• Berth-Jones J. Topical Therapy. In: Rook’s Textbook of Dermatology. Burns T, Breathnach SM, Cox N, Griffiths C (Eds). Blackwell Science, Oxford, UK, 75.1–75.52 (2004).
   Google Scholar
• Roewert-Huber J, Stockfleth E, Kerl H. Pathology and pathobiology of actinic (solar) keratosis – an update. Br. J. Dermatol.157(Suppl. 2), 18–20 (2007).
   PubMed Web of Science ®Google Scholar
• de Becker D, Mcgregor JM, Hughes BR. Guidelines for the management of actinic keratoses. Br. J. Dermatol.156, 222–230 (2007).
   PubMedGoogle Scholar
• Piérard GE, Piérard-Franchimont C, Paquet P, Quatresooz P. Emerging therapies for ionizing radiation-associated skin field carcinogenesis. Expert Opin. Pharmacother.10, 813–821 (2009).
   PubMed Web of Science ®Google Scholar
• Weinstock MA, Lee KC, Chren MM, Marcolivio K; VATTC Trial Group. Quality of life in the actinic neoplasia syndrome: the VA Topical Tretinoin Chemoprevention (VATTC) Trial. J. Am. Acad. Dermatol.61, 207–215 (2009).
   PubMed Web of Science ®Google Scholar
• Jorizzo JL. Current and novel treatment options for actinic keratosis. J. Cutan. Med. Surg.28(Suppl. 3), 13–21 (2008).
   Google Scholar
• McIntyre WJ, Downs MR, Bedwell SA. Treatment options for actinic keratoses. Am. Fam. Physician77, 1078–1079 (2008).
   PubMedGoogle Scholar
• Gupta AK, Kimberley I, Robert W et al. Interventions for actinic keratoses (Protocol for a Cochrane Review). Cochrane Library3, structured abstract (2009).
   Google Scholar
• Thai KE, Fergin P, Freeman M et al. A prospective study of the use of cryosurgery for the treatment of actinic keratoses. Int. J. Dermatol.43, 687–692 (2004).
   PubMed Web of Science ®Google Scholar
• Herd RM, Jury C. Topical 5 fluorouracil for non-melanoma skin cancer (Protocol for a Cochrane Review). Cochrane Library3 (2009).
   Google Scholar
• Askew DA, Mickan SM, Soyer HP, Wilkinson D. Effectiveness of 5-fluorouracil treatment for actinic keratosis – a systematic review of randomized controlled trials. Int. J. Dermatol.48, 453–463 (2009).
   PubMed Web of Science ®Google Scholar
• Jury CS, Ramraka-Jones VS, Gudi V, Herd RM. A randomized trial of topical 5% 5-fluorouracil (Efudix cream) in the treatment of actinic keratoses comparing daily with weekly treatment. Br. J. Dermatol.153, 808–810 (2005).
   PubMedGoogle Scholar
• Epstein E. Does intermittent ‘pulse’ topical 5-fluoruracil therapy allow destruction of actinic keratosis without significant inflammation? J. Am. Acad. Dermatol.38, 77–80 (1998).
   PubMed Web of Science ®Google Scholar
• Gupta AK, Weiss JS, Jorizzo JL. 5-fluorouracil 0.5% cream for multiple actinic or solar keratoses of the face and anterior scalp. Skin Therapy Lett.6, 1–4 (2001).
   PubMedGoogle Scholar
• Weiss J, Menter A, Hevia O et al. Effective treatment of actinic keratosis with 0.5% fluorouracil cream for 1, 2, or 4 weeks. Cutis70(2 Suppl.), 22–29 (2002).
   PubMed Web of Science ®Google Scholar
• Loven K, Stein L, Furst K, Levy S. Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis. Clin. Ther.24, 990–1000 (2002).
   PubMed Web of Science ®Google Scholar
• Jorizzo JL, Carney PS, Ko WT et al. Fluorouracil 5% and 0.5% creams for the treatment of actinic keratosis: equivalent efficacy with a lower concentration and more convenient dosing schedule. Cutis74(6 Suppl.), 18–23 (2004).
   PubMed Web of Science ®Google Scholar
• Kaur RR, Alikhan A, Maibach HI. Comparison of topical 5-fluorouracil formulations in actinic keratosis treatment. J. Dermatolog. Treat. (2009) (Epub ahead of print).
   PubMedGoogle Scholar
• Yentzer B, Hick J, Williams L et al. Adherence to a topical regimen of 5-fluorouracil 0.5% cream for the treatment of actinic keratoses. Arch. Dermatol.145, 203–205 (2009).
   PubMedGoogle Scholar
• Gupta AK. The management of actinic keratoses in the United States with topical fluorouracil: a pharmacoeconomic evaluation. Cutis70(2 Suppl.), 30–36 (2002).
   PubMed Web of Science ®Google Scholar
• Menter A, Vamvakias G, Jorizzo J. One-week treatment with once-daily fluorouracil cream 0.5% in participants with actinic keratoses. Cutis81, 509–516 (2008).
   PubMed Web of Science ®Google Scholar
• Jorizzo J, Weiss J, Vamvakias G. One-week treatment with 0.5% fluorouracil cream prior to cryosurgery in patients with actinic keratoses: a double-blind, vehicle-controlled, long-term study. J. Drugs Dermatol.5, 133–139 (2006).
   PubMedGoogle Scholar
• Mann M, Berk DR, Petersen J. Chemowraps as an adjuvant to surgery for patients with diffuse squamous cell carcinoma of the extremities. J. Drugs Dermatol.7, 685–688 (2008).
   PubMedGoogle Scholar
• Chiarello SE. Cryopeeling (extensive cryosurgery) for treatment of actinic keratoses: an update and comparison. Dermatol. Surg.26, 728–732 (2000).
   PubMed Web of Science ®Google Scholar
• Benedetto AV, Griffin TD, Benedetto EA et al. Dermabrasion: therapy and prophylaxis of the photoaged skin. J. Am. Acad. Dermatol.27, 439–447 (1992).
   PubMedGoogle Scholar
• Monheit GD. Medium-depth chemical peels. Dermatol. Clin.19, 413–425 (2001).
   PubMedGoogle Scholar
• Lawrence N, Cox SE, Cockerell CJ et al. A comparison of the efficacy and safety of Jessner’s solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses. Arch. Dermatol.131, 176–181 (1995).
   PubMed Web of Science ®Google Scholar
• Katz BE. The fluor-hydroxy pulse peel: a pilot evaluation of a new superficial chemical peel. Cosm. Dermatol.8, 24–30 (1995).
   Google Scholar
• Marrero GM, Katz BE. The new fluor-hydroxy pulse peel. A combination of 5-fluorouracil and glycolic acid. Dermatol. Surg.24, 973–978 (1998).
   PubMed Web of Science ®Google Scholar
• Bagatin E, Teixeira SP, Hassun KM et al. 5-fluorouracil superficial peel for multiple actinic keratoses. Int. J. Dermatol.48, 902–907 (2009).
   PubMedGoogle Scholar
• Newman MD, Weinberg JM. Topical therapy in the treatment of actinic keratosis and basal cell carcinoma. Cutis79, 18–28 (2007).
   PubMed Web of Science ®Google Scholar
• Gupta AK, Davey V, Mcphail H. Evaluation of the effectiveness of imiquimod and 5-fluorouracil for the treatment of actinic keratoses: critical review and meta-analysis of efficacy studies. J. Cutan. Med. Surg.9, 209–214 (2005).
   PubMed Web of Science ®Google Scholar
• Krawtchenko N, Roewert-Huber J, Ulrich M et al. A randomized study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br. J. Dermatol.157(Suppl. 2), 34–40 (2007).
   PubMed Web of Science ®Google Scholar
• Tanghetti E, Werschler P. Comparison of 5% 5-fluorouracil cream and 5% imiquimod cream in the management of actinic keratoses on the face and scalp. J. Drugs Dermatol.6, 144–147 (2007).
   PubMedGoogle Scholar
• Price NM. The treatment of actinic keratoses with a combination of 5-fluorouracil and imiquimod creams. J. Drugs Dermatol.6, 778–781 (2007).
   PubMedGoogle Scholar
• Smith SR, Morhenn VB, Piacquadio DJ. Bilateral comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% 5-fluorouracil cream in the treatment of actinic keratoses of the face and scalp. J. Drugs Dermatol.5, 156–159 (2006).
   PubMedGoogle Scholar
• Ostertag JU, Quaedvlieg PJ, van der Geer S et al. A clinical comparison and long-term follow-up of topical 5-fluorouracil versus laser resurfacing in the treatment of widespread actinic keratoses. Lasers Surg. Med.38, 731–739 (2006).
   PubMed Web of Science ®Google Scholar
• Braathen LR, Szeimies RM, Basset-Seguin N et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. J. Am. Acad. Dermatol.56, 125–143 (2007).
   PubMed Web of Science ®Google Scholar
• Morton C, Campbell S, Gupta G et al. Intraindividual, right-left comparision of topical methyl aminolaevulinate-photodynamic therapy and cryotherapy in subjects with actinic keratoses: a multicentre, randomized, controlled study. Br. J. Dermatol.155, 1029–1036 (2006).
   PubMed Web of Science ®Google Scholar
• Tschen EH, Wong DS, Pariser DM et al. Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: phase IV multicentre clinical trail with 12-month follow-up. Br. J. Dermatol.155, 1262–1269 (2006).
   PubMed Web of Science ®Google Scholar
• Caekelbergh K, Annemans L, Lambert J et al. Economic evaluation of methyl aminolevulinate-based photodynamic therapy in the management of actinic keratosis and basal cell carcinoma. Br. J. Dermatol.155, 784–790 (2006).
   PubMed Web of Science ®Google Scholar
• Gilbert DJ. Treatment of actinic keratoses with sequential combination of 5-fluorouracil and photodynamic therapy. J. Drugs Dermatol.4, 161–163 (2005).
   PubMedGoogle Scholar
• Anand S, Honari G, Hasan T et al. Low-dose methotrexate enhances aminilevulinate-based photodynamic therapy in skin carcinoma cells in vitro and in vivo. Clin. Cancer Res.15, 3333–3343 (2009).
   PubMed Web of Science ®Google Scholar
• Perrett CM, McGregor JM, Warwick J et al. Treatment of post-transplant premalignant skin disease: a randomized intra-patient comparative study of 5-fluorouracil cream and topical photodynamic therapy. Br. J. Dermatol.156, 320–328 (2007).
   PubMed Web of Science ®Google Scholar
• Gold MH. Pharmacoeconomic analysis of the treatment of multiple actinic keratoses. J. Drugs Dermatol.7, 23–25 (2008).
   PubMedGoogle Scholar
• Hantash BM, Stewart DB, Cooper ZA et al. Facial resurfacing for nonmelanoma skin cancer prophylaxis. Arch. Dermatol.142, 976–982 (2006).
   PubMedGoogle Scholar
• Olsen EA, Katz I, Levine N et al. Tretinoin emollient cream for photodamaged skin: results of a 48-week, multicenter, double-blind study. J. Am. Acad. Dermatol.37, 217–226 (1997).
   PubMed Web of Science ®Google Scholar
• Ye JN, Rhew DC, Yip F, Edelstein L. Extramammary Paget’s disease resistant to surgery and imiquimod monotherapy but responsive to imiquimod combination topical chemotherapy with 5-fluorouracil and retinoic acid: a case report. Cutis77, 245–250 (2006).
   PubMedGoogle Scholar
• Kim JJ, Chang MW, Shwayder T. Topical tretinoin and 5-fluorouracil in the treatment of linear verrucous epidermal nevus. J. Am. Acad. Dermatol.43, 129–132 (2000).
   PubMed Web of Science ®Google Scholar
• Nijsten TE, Stern RS. Oral retinoid use reduces cutaneous squamous cell carcinoma risk in patients with psoriasis treated with psoralen-UVA: a nested cohort study. J. Am. Acad. Dermatol.49, 644–650 (2003).
   PubMed Web of Science ®Google Scholar
• Harwood CA, Leedham-Green M, Leig IM et al. Low doses of retinoids in the prevention of squamous cell carcinoma in transplant patients: a 16 year retrospective study. Arch. Dermatol.41, 456–464 (2005).
   Google Scholar
• Sander CA, Pfieffer C, Kligman AM et al. Chemotherapy for disseminated actinic keratosis with 5-fluorouracil and isotretinoin. J. Am. Acad. Dermatol.36, 236–238 (1997).
   PubMedGoogle Scholar
• Gross K, Kircik L, Kricorian G. 5% 5-fluorouracil cream for the treatment of small superficial basal cell carcinoma: efficacy, tolerability, cosmetic outcome, and patient satisfaction. Dermatol. Surg.33, 433–439 (2007).
   PubMed Web of Science ®Google Scholar
• Moore AY. Clinical applications for topical 5-fluorouracil in the treatment of dermatological disorders. J. Dermatolog. Treat.1, 1–8 (2009).
   Google Scholar
• Bargman H, Hochman J. Topical treatment of Bowen’s disease with 5-fluorouracil. J. Cutan. Med. Surg.7, 101–105 (2003).
   PubMed Web of Science ®Google Scholar
• Graham BD, Jetmore AB, Foote JE, Arnold LK. Topical 5-fluorouracil in the management of extensive anal Bowen’s disease: a preferred approach. Dis. Colon Rectum48, 444–450 (2005).
   PubMedGoogle Scholar
• Ondo AL, Mings SM, Pestak RM, Shanler SD. Topical combination therapy for cutaneous squamous cell carcinoma in situ with 5-fluorouracil cream and imiquimod cream in patients who have failed topical monotherapy. J. Am. Acad. Dermatol.55, 1092–1094 (2006).
   PubMed Web of Science ®Google Scholar
• Salim A, Leman JA, McColl JH et al. Randomized comparison of photodynamic therapy with topical 5-fluorouracil in Bowen’s disease. Br. J. Dermatol.148, 539–543 (2003).
   PubMed Web of Science ®Google Scholar
• Morton C, Horn M, Leman J et al. Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or fluorouracil for treatment of squamous cell carcinoma in situ: results of a multicenter randomized trial. Arch. Dermatol.142, 729–735 (2006).
   PubMedGoogle Scholar
• Gladsjo JA, Alió Sáenz AB, Bergman J et al. 5% 5-fluorouracil cream for treatment of verruca vulgaris in children. Pediatr. Dermatol.26, 279–285 (2009).
   PubMedGoogle Scholar
• Salk RS, Grogan KA, Chang TJ. Topical 5% 5-fluorouracil cream in the treatment of plantar warts: a prospective, randomized, and controlled clinical study. J. Drugs Dermatol.5, 418–424 (2006).
   PubMedGoogle Scholar
• Luk NM, Tang WY, Chan SW et al. Topical 5-fluorouracil has no additional benefit in treating common warts with cryotheraphy: a single-centre, double blind, randomized, placebo-controlled trial. Clin. Exp. Dermatol.31, 394–397 (2006).
   PubMedGoogle Scholar
• Gibbs S, Harvey I. Topical treatments for cutaneous warts. Cochrane Database Syst. Rev.19(3), CD001781 (2006).
   Google Scholar
• Fox PA, Tung MY. Human papillomavirus: burden of illness and treatment cost considerations. Am. J. Clin. Dermatol.6, 365–381 (2005).
   PubMedGoogle Scholar
• Pérez-Blanco M, Hernández Valles R, García-Humbria L, Yegres F. Chromoblastomycosis in children and adolescents in the endemic area of the Falcón State, Venezuela. Med. Mycol.44, 467–471 (2006).
   PubMed Web of Science ®Google Scholar
• Berman B, Villa AM, Ramirez CC. Novel opportunities in the treatment and prevention of scarring. J. Cutan. Med. Surg.8(Suppl. 3), 32–36 (2004).
   PubMedGoogle Scholar
• Velasco S, Guillet G. Improvement of Darier’s disease on treatment with topical 5-fluorouracil. Ann. Dermatol. Venereol.133, 366–368 (2006).
   PubMedGoogle Scholar
• Teixeira SP, Nascimento MM, Bagatin E et al. The use of fluor-hydroxy pulse peel in actinic porokeratosis. Dermatol. Surg.31, 1145–1148 (2005).
   PubMedGoogle Scholar
• van Ruth S, Jansman FG, Sanders CJ. Total body topical 5-fluorouracil for extensive non-melanoma skin cancer. Pharm. World Sci.28, 159–162 (2006).
   PubMedGoogle Scholar
• Yesudian PD, King CM. Allergic contact dermatitis from stearyl alcohol in Efudix cream. Contact Dermatitis45, 313–314 (2001).
   PubMedGoogle Scholar
• Farrar CW, Bell HK, King CM. Allergic contact dermatitis from propylene glycol in Efudix cream. Contact Dermatitis48, 345 (2003).
   PubMedGoogle Scholar
• Meijer BU, de Waard-van der Spek FB. Allergic contact dermatitis because of topical use of 5-fluorouracil (Efudix® cream). Contact Dermatitis57, 58–60 (2007).
   PubMedGoogle Scholar
• Levy S, Furst K, Chern W. A pharmacokinetic evaluation of 0.5% and 5% fluorouracil topical cream in patients with actinic keratosis. Clin. Ther.23, 908–920 (2001).
   PubMed Web of Science ®Google Scholar
• Levy S, Furst K, Chern W. A novel 0.5% fluorouracil cream is minimally absorbed into the systemic circulation yet is as effective as 5% fluorouracil cream. Cutis70, 14–21 (2002).
   PubMedGoogle Scholar